Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

The Wisconsin Department of Health Services (DHS) awarded agencies in communities across the state more than $21 million from ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

The news caused a significant decline in the price of Zeta stock. On November 13, 2024, the price of the company's stock fell 37%, from a closing price of $28.22 per share on November 12, 2024, to $17 ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

A new study from the Tippie College of Business finds that many drug prices actually drop after pharmaceutical company ...

EST Catalyst Pharmaceuticals (CPRX) reports settlement of Firdapse patent litigation with Teva (TEVA) Stay Ahead of the Market:Discover ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...